71
Views
5
CrossRef citations to date
0
Altmetric
Review

Improving management of patients with advanced cancer

Pages 415-424 | Published online: 02 Dec 2010

References

  • ColemanREBisphosphonates: clinical experienceOncologist20049Suppl 4142715459426
  • FitchMMaxwellCRyanCLothmanHDrudge-CoatesLCostaLBone metastases from advanced cancers: clinical implications and treatment optionsClin J Oncol Nurs200913670171019948468
  • LiptonABisphosphonate therapy in the oncology settingExpert Opin Emerg Drugs20038246948814662000
  • ColemanREMetastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat Rev200127316517611417967
  • LiptonATreatment of bone metastases and bone pain with bisphosphonatesSupport Cancer Ther2007429210018632473
  • Aredia [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2008
  • Zometa [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2009
  • Ostac [package insert]Nutley, NJHoffmann-La Roche2004
  • Bondronat [summary of product characteristics]Welwyn Garden City, UKRoche Products Ltd2007
  • PavlakisNSchmidtRStocklerMBisphosphonates for breast cancerCochrane Database Syst Rev20053CD00347416034900
  • AaproMAbrahamssonPABodyJJGuidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panelAnn Oncol200819342043217906299
  • KohnoNAogiKMinamiHZoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialJ Clin Oncol200523153314332115738536
  • HortobagyiGNTheriaultRLPorterLEfficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study GroupN Engl J Med199633524178517918965890
  • HortobagyiGNTheriaultRLLiptonALong-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study GroupJ Clin Oncol1998166203820449626201
  • BodyJJDielIJLichinitserMRIntravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnn Oncol20031491399140512954579
  • BodyJJDielIJBellROral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerPain2004111330631215363874
  • KristensenBEjlertsenBGroenvoldMHeinSLoftHMouridsenHTOral clodronate in breast cancer patients with bone metastases: a randomized studyJ Intern Med19992461677410447227
  • PatersonAHPowlesTJKanisJAMcCloskeyEHansonJAshleySDouble-blind controlled trial of oral clodronate in patients with bone metastases from breast cancerJ Clin Oncol199311159658418243
  • Tubiana-HulinMBeuzebocPMauriacL[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]Bull Cancer200188770170711495824
  • MajorPPCookRJChenBLZhengMSurvival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumorsSupport Cancer. Ther20052423424018628179
  • ColemanRESkeletal complications of malignancyCancer1997808 Suppl158815949362426
  • PayneRPharmacologic management of bone pain in the cancer patientClin J Pain19895Suppl 2S43S49 discussion follows.2520440
  • ReichCDAdvances in the treatment of bone metastasesClin J Oncol Nurs20037664164614705479
  • BarnettMLHypercalcemiaSemin Oncol Nurs199915319020110461704
  • MaxwellCRole of the nurse in preserving patients’ independenceEur J Oncol Nurs200711Suppl 2S38S4117768093
  • MaxwellCSwiftRGoodeMDoaneLRogersMAdvances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acidClin J Oncol Nurs20037440340812929273
  • RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J20017537738711693896
  • DielIJBergnerRGrotzKAAdverse effects of bisphosphonates: current issuesJ Support Oncol200751047548218240669
  • BerensonJRRosenLSHowellAZoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer20019171191120011283917
  • HoffAOTothBBAltundagKFrequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonatesJ Bone Miner Res200823682683618558816
  • McArthurHLEstiloCHurynJOsteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). [abstract]J Clin Oncol200826Suppl 15523s Abstract 9588.
  • HenryDvon MoosRVadhan-RajSA double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [abstract]Eur J Cancer Suppl20097311 Abstract 20LBA.
  • StopeckATLiptonABodyJJDenosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJ Clin Oncol2010118 [Epub ahead of print].
  • ColemanRBundredNde BoerRImpact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. [abstract]Cancer Res200969Suppl 24733s Abstract 4082.
  • DimopoulosMAKastritisEBamiaCReduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acidAnn Oncol200920111712018689864
  • RipamontiCIManiezzoMCampaTDecreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates The experience of the National Cancer Institute of MilanAnn Oncol200920113714518647964
  • ChowEBottomleyAUnderstanding the EORTC QLQ-BM22, the module for patients with bone metastasesExpert Rev Pharmacoecon Outcomes Res20099546146519817529
  • ChowEHirdAVelikovaGThe European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22Eur J Cancer20094571146115219097882
  • SchumacherKLKoresawaSWestCThe usefulness of a daily pain management diary for outpatients with cancer-related painOncol Nurs Forum20022991304131312370700
  • WardleyADavidsonNBarrett-LeePZoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administrationBr J Cancer200592101869187615870721
  • CostaLBadiaXChowELiptonAWardleyAImpact of skeletal complications on patients’ quality of life, mobility, and functional independenceSupport Care Cancer200816887988918392862
  • WongRWiffenPJBisphosphonates for the relief of pain secondary to bone metastasesCochrane Database Syst Rev20022CD00206812076438
  • Drudge-CoatesLThompsonPMMuirGHBurden of bone metastases from renal cell carcinoma: zoledronic acid and functional independence[poster]Societe Internationale d’Urologie (SIU) World Uro-Oncology Update2008 Nov 19–22Santiago, Chile Abstract UP-18.
  • MangiapaneSHoerAGotheHBarghoutVHaeusslerBHigher persistency with i.v. bisphosphonates in patients with bone metastasis. [abstract]J Clin Oncol200624Suppl 18698s Abstract 18623.
  • RabendaVHiligsmannMReginsterJYPoor adherence to oral bisphosphonate treatment and its consequences: a review of the evidenceExpert Opin Pharmacother200910142303231519640210
  • FallowfieldLStebbingJBraybrookeJLangridgeCJenkinsVThe preferences and experiences of different bisphosphonate treatments in women with breast cancerPsycho-oncology2010524 [Epub ahead of print].
  • HatoumHTLinSJSmithMRBarghoutVLiptonAZoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims databaseCancer200811361438144518720527
  • FitchMIMaxwellCBisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient educationOncol Nurs Forum200835470971318591175
  • ColemanREWinterMCCameronDThe effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBr J Cancer201010271099110520234364
  • MorganGDaviesFGregoryWEvaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study. [abstract]J Clin Oncol201029Suppl 15578s Abstract 8021.
  • ZaghloulMSBoutrusREl-HossienyHKaderYAEl-AttarINazmyMA prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancerInt J Clin Oncol201015438238920354750
  • ZarogoulidisKBoutsikouEZarogoulidisPThe impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasisInt J Cancer200912571705170919521984
  • BodyJ-JCookRCostaLPossible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. [poster]The IX International Meeting on Cancer Induced Bone Disease2009 Oct 28–31Arlington, VA Poster 71.
  • CostaLCookRBodyJ-JZoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption. [poster]The IX International Meeting on Cancer Induced Bone Disease2009 Oct 28–31Arlington, VA Poster 50.
  • GnantMMlineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
  • RennertGPinchevMRennertHSUse of bisphosphonates and risk of postmenopausal breast cancerJ Clin Oncol201028223577358120567021
  • NewcombPATrentham-DietzAHamptonJMBisphosphonates for osteoporosis treatment are associated with reduced breast cancer riskBr J Cancer2010102579980220160722
  • ChlebowskiRTChenZCauleyJAOral bisphosphonate use and breast cancer incidence in postmenopausal womenJ Clin Oncol201028223582359020567009